Atorvastatin Study For The Treatment Of High Cholesterol In Patients From Thailand
- Registration Number
- NCT00647543
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Brief Summary
The purpose of this study is to evaluate the efficacy of atorvastatin in lowering cholesterol on patients from Thailand with high cholesterol.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 242
Inclusion Criteria
- Dyslipidemic patients who were eligible for lipid lowering therapy
- Willingness to follow study diet for 1 month prior to screening and for the duration of the study
Exclusion Criteria
- Use of other lipid lowering agents (6-week washout period)
- Uncontrolled high blood pressure
- Impaired liver function
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description High Risk Atorvastatin - Low Risk Atorvastatin - Medium Risk Atorvastatin -
- Primary Outcome Measures
Name Time Method Percentage of patients who achieved low-density lipoprotein cholesterol (LDL-C) target Week 8
- Secondary Outcome Measures
Name Time Method Change and percent change from baseline in high-density lipoprotein cholesterol (HDL-C) Weeks 2, 4, and 8 Change and percent change from baseline in LDL/HDL ratio Weeks 2, 4, and 8 Change and percent change from baseline in total cholesterol Weeks 2, 4, and 8 Change and percent change from baseline in triglycerides Weeks 2, 4, and 8 Adverse events and laboratory test changes Weeks 2, 4, and 8 Percentage of patients who achieved LDL-C target Weeks 2 and 4, and Week 8 with 1 step titration Change and percent change from baseline in LDL-C Weeks 2, 4, and 8
Trial Locations
- Locations (1)
Pfizer Investigational Site